<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14780">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675908</url>
  </required_header>
  <id_info>
    <org_study_id>356090</org_study_id>
    <nct_id>NCT01675908</nct_id>
  </id_info>
  <brief_title>Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression</brief_title>
  <official_title>Multicenter Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the performance of full covered metal stents and plastic stents for preoperative
      biliary decompression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Covered self expandable metal stents (CSEMS) are three times larger in diameter than 10 Fr
      plastic stents. When compared to plastic stents, randomized trials have shown longer patency
      and fewer stent-related complications for CSEMS. The investigators hypothesize that
      placement of CSEMS would be a better treatment option for preoperative biliary decompression
      in patients with pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complications related to stent dysfunction</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the rates of complications (%) related to stent dysfunction which include persistent hyperbilirubinemia and cholangitis  that warrant stent exchange by a repeat ERCP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be measured as proportion of patients who encounter a procedural complication (%) during ERCP that includes pancreatitis, perforation or hemorrhage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Obstructive Jaundice</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Metal stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plastic Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent Dysfunction</intervention_name>
    <description>Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.</description>
    <arm_group_label>Metal stent</arm_group_label>
    <arm_group_label>Plastic Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Complications</intervention_name>
    <description>Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.</description>
    <arm_group_label>Metal stent</arm_group_label>
    <arm_group_label>Plastic Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Patients with pancreatic cancer and mass in the head of pancreas causing jaundice.

          2. Patients 19 yrs of age and older

          3. Serum bilirubin &gt; 2mg/dl

          4. CT: No evidence of distant metastasis or local vascular invasion (tumor surrounding
             portal or mesenteric vessels for more than 180 degrees of their circumference or an
             irregular vessel margin).

        EXCLUSION CRITERIA:

          1. Karnofsky score &lt; 60

          2. Prior (ERCP or PTC) attempts at biliary decompression for the same indication

          3. Tumor-related gastric outlet obstruction (vomiting and oral intake of &lt; 1L/day)

          4. Ongoing or planned neoadjuvant therapy

          5. Cholangitis at presentation or coagulopathy needing reversal medication

          6. Post-surgical anatomy

          7. Multiple extra-hepatic biliary strictures or concomitant stricture in liver hilum

          8. Failed ERCP's (Definition: Inability to deploy a biliary stent thereby requiring a
             PTC or surgery).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shyam varadarajulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Center for Interventional Endoscopy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shyam varadarajulu, MD</last_name>
    <email>svaradarajulu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shyam varadarajulu, MD</last_name>
      <phone>407-303-2570</phone>
      <email>svaradarajulu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>shyam varadarajulu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Goldberg, MD</last_name>
      <email>egoldber@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>eric goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Yachimski, MD</last_name>
      <email>patrick.yachimski@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Yachimski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
